absolutely and the first part of the trial just passed was short and mixed dose. The one being recruited for will be representative and potentially show enhanced data points with the best dose and duration. I also read somewhere might have been on one of these threads that they feel it’s one of more potent fak inhibitors in vitro so far based on comparative data but I might be wrong. Dyor
Ann: Preliminary Final Report and Annual Report YE 31 March 2024, page-6
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
-0.005(3.33%) |
Mkt cap ! $39.84M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 14.5¢ | $47.81K | 319.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 161129 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |